EVALUATION OF THE COGNITIVE IMPAIRMENT IN MULTIPLE SCLEROSIS

Öz

Objective Multiple sclerosis (MS) is a chronic-imflammatory demyelinating central nervus system disease affecting mainly the white matter. Cognitive impairment is a common problem in relapsing-remitting multiple sclerosis (RRMS) patients and plays a major role in the quality of life. Cognitive impairment occurs in 30-70% of patients with MS. Deficits typically occur in memory, attention and information processing functions. In this study it is aimed to determine pattern of cognitive impairment in MS patients who are in the early hase of disease. Material and Method Thirty RRMS patients and 30 healthy volunteers were included in the study. All subjects were administered a comprehensive neuropsychological test battery which encompases verbal and visual memory, attention, executive functions, visual spatial functions, language and general fluid intelligence. The relation of disability and functionality with affected cognitive domains were also evaluated. Results There was no significant difference mean age and duration of education between the MS patients and healthy controls. Mean duration of disease in MS patients is 62.20 ± 52.70 mounth and mean time to diagnosis is 39.16 ± 39.17 mounth, Mean number of attack is 3.13 ± 1.90 and mean EDSS score is 1.38 ± 1.31. In Trail Making Test A and B, which is a test that evaluates psychomotor speed and attention functions, patients with MS had significantly lower performance than control group. Conclusion MS patient exhibited a worse performance in all tests evaluating attention and executive functions. This worse performance was correlated with Multiple Sclerosis Functional Composite (MSFC) and Expanded Diasability Status Scale (EDSS). MS patients are reported to have mainly memory and attention deficits. Our results suggest that a working memory and attention deficits and executive dysfunction may associate with other findings of the disease since early phases of disease.

Anahtar Kelimeler

• MULTIPLE SCLEROSİS
• ATTENTION
• MEMORY
• EXECUTIVE FUNCTIONS
• VISUAL-SPATIAL FUNCTIONS
• MSFC
• EDSS

MULTİPL SKLEROZDA KOGNİTİF ETKİLENMENİN DEĞERLENDİRİLMESİ

Öz

Amaç Multipl skleroz (MS), santral sinir sisteminin ön planda beyaz cevherini etkileyen kronik inflamatuar demiyelinizan hastalığıdır. Kognitif bozukluk relapsing remitting multipl skleroz (RRMS) hastalarında sık karşılaşılan bir sorundur ve yaşam kalitesi üzerinde önemli rol oynamaktadır. MS hastalarının %30-70’inde kognitif bozukluk görülür. Bozukluklar tipik olarak bellek, dikkat, bilgi işleme fonksiyonlarındadır. Bu çalışmada erken evre MS hastalarındaki bilişsel bozulmanın paterninin belirlenmesi amaçlanmıştır. Gereç ve Yöntem Çalışmaya 30 RRMS hastası ve 30 sağlıklı gönüllü dahil edilmiştir. Tüm deneklere sözel ve görsel bellek, dikkat, yürütücü işlevler, görsel-uzamsal işlevler, lisan ve genel akıcı zekayı kapsayan geniş bir nöropsikolojik test bataryası uygulanmıştır. Özürlülük ve işlevselliğin etkilenen kognitif alanlarla ilişkisi değerlendirilmiştir. Bulgular Çalışmaya alınan MS hastaları ve sağlıklı gönüllülerin ortalama yaş ve eğitim süreleri arasında anlamlı bir farklılık yoktu. MS’li hastalarda ortalama hastalık süresi 62.20 ± 52.70 ay ve ortalama tanı alma süresi 39.16 ± 39.17 ay idi. Ortalama atak sayısı 3.13 ± 1.90 idi. Ortalama EDSS puanı 1.38 ± 1.31 idi. Psikomotor hız ve dikkat işlevlerini değerlendiren bir test olan İz Sürme Testi A ve B alt-testlerinde MS’li hastaların başarımı kontrol grubundakinden belirgin derecede daha düşüktü (p=0.005). Sonuç MS hastaları dikkat ve yürütücü işlevleri değerlendiren tüm testlerde daha kötü bir başarım sergilemiştir. Bu kötü başarım Multipl Skleroz İşlevsel Bileşiği (MSFC) ve Genişletilmiş Özürlülük Durum Ölçeği (EDSS) ile bağıntılıdır. MS hastalarında temel olarak bellek ve dikkat bozuklukları bildirilmiştir. Bulgularımız çalışma belleği, dikkat ve yürütücü işlev bozukluğunun hastalığın erken evrelerinden itibaren diğer bulgulara eşlik edebileceğini düşündürmektedir.

Anahtar Kelimeler

• MULTİPL SKLEROZ
• BELLEK
• DİKKAT
• YÜRÜTÜCÜ İŞLEVLER
• GÖRSEL-UZAMSAL İŞLEVLER
• MSFC
• EDSS

Kaynakça

1. 1. Beatty WM, Blanco CR, Wilbanks SL et al. Demographic, clinical and cognitive characteristics of multiple sclerosis patients who continue to work. J Neurol Rehab 1995; 9:167-73.
2. 2. Benedict RH, Cookfair D, Gavett R et al. Validity of the minimal assessment of cognitive function in multiple sclerosis. J Int Neuropsychol Soc 2006;12:549-58.
3. 3. Amato MP, Ponziani G, Siracusa G, Sorbi S. Cognitive dysfunction in early onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol 2001; 58:1602-06.
4. 4. Christodoulou C, MacAllister WS, McLinskey NA, Krupp LB. Treatment of cognitive impairment in Multiple sclerosis is the use of acetylcholinesterase inhibitors a viable option CNS drugs 2008; 22:87-97.
5. 5. Drake MA, Carra A, Allegri RF, Luetic G. Differential patterns of memory performance in relapsing-remitting and secondary progressive multiple sclerosis Neurol India 2006;54:370-6.
6. 6. Ruano L, Portaccio E, Goretti B, Niccolai C, Severo M, Patti F et al. Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes. Mult Scler. 2017;23:1258-67.
7. 7. Branco M, Ruano L, Portaccio E, Goretti B, Niccolai C, Patti F et al. Aging with multiple sclerosis: prevalence and profile of cognitive impairment. Neurol Sci. 2019;40:1651-7
8. 8. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the Mc- Donald criteria. Ann Neurol. 2011;69(2):292-302. doi: 10.1002/ ana.223666-

9. 9. Beck AT, Ward C, Mendelson M. Beck depression inventory (BDI). Arch Gen Psychiatry 1961;4(6):561-571
10. 10. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-52.).
11. 11. Lezak MD. Neuropsychological assessment. 3rd ed. New York: Oxford University Pres 1995
12. 12. Cutter GR, Baier ML, Rudick RA et al. Development of a multiple sklerosis functional composite as a clinical trial outcome measure. Brain 1999; 122:871-82
13. 13. Fischer JS, Rudick RA, Cutter GR, Reingold SC. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler. 1999;5(4):244-50. doi: 10.1177/135245859900500409.
14. 14. Tuncer N. Multipl sklerozlu olgularda kognitif fonksiyon bozuklukları. Turkiye Klinikleri 2006; 26:559-64.
15. 15. Rao SM. Neuropsychological aspects of multiple sclerosis. Ed: Raine CS, Mc Farland HF, Tourellotte WW, Clinical and pathogenetic Basis. pp.357-362. Chapman and Hall, London, UK, 1997.
16. 16. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. Neurology. 1991;41(5):685-91.
17. 17. Janculjak D, Mubrin A, Brinar V et al. Changes of attention and memory in a group of patients with multipl sclerosis. Clin Neurol Neurosurg 2002; 104:221-7.
18. 18. Ünal A. Multipl skleroz hastalarında bilişsel işlev bozuklukları ve tedavisi (Ed: Kırbaş D) Nöropsikiyatri (Nörolojik Hastalıkların Psikiyatrik Yönü) s.221-240, İstanbul, 2006.
19. 19. Roca M, Torralva T, Meli F, Fiol M, Calcagno M, Carpintiero S, De Pino G, Ventrice F, Martin M, Vita L, Manes F, Correale J Cognitive defisits in multiple sclerosis Correlate with changes in fronto-subcortical tracts . Mult Scler 2008;14:364-69.
20. 20. Achiron A, M Polliack, SM Rao. Cognitive patterns and progression in multiple sclerosis: construction and validation of percentile curves. J. Neurol. Neurosurg. Psychiatry 2005;76:744-749.
21. 21. Bagert B, Camplair P, Bourdette D. Cognitive dysfunction in multiple sclerosis. Natural history, Pathophysiology and Management. CNS Drugs 2002;16:445-55.
22. 22. Chiaravalloti ND, Deluca J. Cognitive impairment in multiple sclerosis. Lancet Neurol 2008;7(12):1139-1151.
23. 23. Winkelmann A, Engel C, Apel A. Cognitive impairment in multiple sclerosis. J Neurol 2008;255(2):309-310.
24. 24. Mollahasanoğlu A. Normal deneklerde bir grup görsel ve sözel bellek testleri performansına yaş ve eğitimin etkisi. Yüksek lisans tezi, İstanbul, 2002.
25. 25. Foong J, Rozewicz L, Chong WK, Thompson AJ, Miller DH, Ron MA. A comparison of neuropsychological deficits in primary and secondary progressive multiple sclerosis. J Neurol 2000; 247:97-101.
26. 26. Pujol J, Vendrell P, Deus J, Junqu´e C, Bello J, Mart´ı-Vilalta JL. The effect of medial frontal and posterior parietal demyelinating lesions on stroop interference. Neuroimage 2000; 13:68-75.
27. 27. Öktem Ö. Mental Durum Muayenesi. In: Nöroloji (Ed.E.Öge). Nobel Tıp Kitabevi, İstanbul, 2004; 125-26.
28. 28. Özakbas S, Çagiran I, Örmeci B, İdiman E. Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis. J Neurol Sci 2004;208:3-7.
29. 29. Kujala P, Portin R, Ruutiainen J. Brain 1997;120:289-97.
30. 30. Ruggiari RM, Palermo R, Vitello G, Gennuso M, Settipani N, Piccoli F. Cognitive impairment in patients suffering from relapsing- remitting multiple sclerosis with EDSS < or = 3.5. Acta Neurol Scand 2003;108:323-26.
31. 31. Patti F, Amato MP, Tola MA, Trojano M, Ferrazza F, Lijoi AF, Bastianell S. Relationship between cognitive impairment and magnetic resonance imaging disease parameters in patients with early relapsing-remiting multiple sclerosis: results from teh multicenter COGIMUS study. Neurol 2008; 70:4-170.